Clinical Trial Update: Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients

View source ↗

Summary

The trial assessed the CMV-specific ELISPOT assay as a predictor of CMV infection in kidney transplant recipients and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Snippet

Sponsor: Asan Medical Center | Conditions: Kidney Transplantation Recipients | Status: COMPLETED